This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lucatumumab
- DrugBank Accession Number
- DB06360
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Lucatumumab
- External IDs
- CHIR-12.12
- HCD-122
- HCD122
Pharmacology
- Indication
Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.
Target Actions Organism UTumor necrosis factor receptor superfamily member 5 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Lucatumumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Lucatumumab. Aducanumab The risk or severity of adverse effects can be increased when Lucatumumab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab. Alirocumab The risk or severity of adverse effects can be increased when Lucatumumab is combined with Alirocumab. Amivantamab The risk or severity of adverse effects can be increased when Lucatumumab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Lucatumumab is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Lucatumumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Lucatumumab is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Lucatumumab is combined with Antilymphocyte immunoglobulin (horse). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P0EP9VFC4R
- CAS number
- 903512-50-5
References
- General References
- Not Available
- External Links
- Wikipedia
- Lucatumumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Follicular Lymphoma ( FL) 1 1 Completed Treatment Multiple Myeloma (MM) 1 1 Terminated Treatment Chronic Lymphocytic Leukemia 1 1, 2 Completed Treatment Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Non-Hodgkin's Lymphomas 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ubiquitin protein ligase binding
- Specific Function
- Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
- Gene Name
- CD40
- Uniprot ID
- P25942
- Uniprot Name
- Tumor necrosis factor receptor superfamily member 5
- Molecular Weight
- 30618.76 Da
Drug created at March 19, 2008 16:27 / Updated at February 21, 2021 18:52